Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse effects

Bacillus Calmette‐Guérin (BCG) showed no clear difference in serious adverse effects compared with mitomycin C (MMC) (low certainty).

1 finding from 1 review

Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer 2020 · Cochrane Headline outcomes only
RR 2.31 [0.82, 6.52]
5 studies · 1024 participants
Low